Clinical Trial Update: Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating flavopiridol in patients with recurrent or metastatic head and neck cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Flavopiridol (alvocidib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Head and Neck Cancer, Thromboembolism | Phase 2 | Status: COMPLETED